check_circleStudy Completed
Carcinoma, Renal Cell, Carcinoma, Renal Cell (Advanced)
Bayer Identifier:
13102
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®
Trial purpose
Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.
Key Participants Requirements
Sex
BothAge
18 - N/ATrial summary
Enrollment Goal
71Trial Dates
June 2008 - November 2010Phase
N/ACould I Receive a placebo
NoProducts
Nexavar (Sorafenib, BAY43-9006)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Belgium |
Primary Outcome
- Proportion of patients who are progression-free at one year according to the RECIST criteria. The proportion of patients who are progression-free at 1, 3, 6 and 9 months will also be calculateddate_rangeTime Frame:At 1, 3, 6 and 9 months and after one yearenhanced_encryptionnoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A